WINTON GROUP Ltd - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 28 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
WINTON GROUP Ltd ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$63,000
-58.6%
190,146
-9.8%
0.00%
-50.0%
Q2 2020$152,000
+590.9%
210,815
+211.7%
0.00%
+300.0%
Q1 2020$22,000
+29.4%
67,643
+177.1%
0.00%
Q4 2019$17,00024,4110.00%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q4 2019
NameSharesValueWeighting ↓
Stonepine Capital Management, LLC 535,590$2,705,0001.58%
Millrace Asset Group, Inc. 200,000$1,010,0000.79%
Private Wealth Partners, LLC 1,000,000$5,050,0000.77%
PERKINS CAPITAL MANAGEMENT INC 249,700$1,261,0000.76%
Timpani Capital Management LLC 206,119$1,041,0000.30%
Diametric Capital, LP 64,329$325,0000.28%
Granahan Investment Management 941,170$4,753,0000.26%
Kalos Management, Inc. 69,900$308,0000.16%
SYMMETRY PEAK MANAGEMENT LLC 85,000$429,0000.15%
B. Riley Wealth Advisors, Inc. 250,000$1,263,0000.15%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders